CMPX · XBRL financial data

Compass Therapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CMPX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021†Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Research and development	14,904	—	—	38,120	42,342	55,969
General and administrative	12,908	10,927	11,658	12,243	15,133	16,870
Total operating expenses	27,812	81,882	41,655	50,363	57,475	72,839
Operating income (loss)	(27,812)	(81,882)	(41,655)	(50,363)	(56,625)	(72,839)
Interest income	88	29	2,360	7,869	7,300	6,400
Interest expense	908	370	0	—	—	—
Other income (expense)	(748)	(299)	2,430	7,869	7,250	6,350
Income tax expense (benefit)	32	0	0	0	0	0
Net income (loss)	(29,500)	(82,181)	(39,225)	(42,494)	(49,375)	(66,489)
Earnings per share, basic USD per share	—	(1.31)	(0.37)	(0.33)	(0.36)	(0.42)
Weighted average shares, basic thousands of shares	—	62,870	105,186	127,027	137,384	157,695
Weighted average shares, diluted thousands of shares	—	—	—	—	137,400	—

† Share count changed about 2x in the period ending 2021-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (CMPX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021†Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	47,076	144,514	34,946	24,228	43,483	30,643
Marketable securities	—	0	151,663	128,233	83,239	178,263
Prepaid and other current assets	3,126	2,591	8,182	1,420	6,029	913
Total current assets	50,202	147,105	194,791	153,881	132,751	209,819
Property and equipment, net	1,126	2,243	1,567	898	353	102
Right-of-use asset	0	4,089	2,967	1,776	6,731	9,099
Total assets	51,911	153,757	199,645	156,875	140,403	219,588
Accounts payable	1,061	867	3,382	4,090	2,249	1,585
Accrued liabilities	1,571	8,775	11,690	2,514	6,287	11,383
Current portion of long-term debt	7,467	0	—	—	—	—
Total current liabilities	10,099	10,631	16,169	7,801	8,874	13,968
Long-term debt	1,867	0	—	—	—	—
Lease liability, non-current	0	3,048	1,838	536	6,296	8,829
Total liabilities	11,966	13,679	18,007	8,337	15,170	22,797
Accumulated deficit	(151,408)	(233,589)	(272,814)	(315,308)	(364,683)	(431,172)
Total stockholders' equity	39,945	140,078	181,638	148,538	125,233	196,791
Total liabilities and equity	51,911	153,757	199,645	156,875	140,403	219,588
Common shares outstanding (cover page) thousands of shares	52,112	101,303	126,507	137,589	138,282	180,088

† Share count changed about 2x in the period ending 2021-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (CMPX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021†Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(29,500)	(82,181)	(39,225)	(42,494)	(49,375)	(66,489)
Stock-based compensation	4,016	4,029	5,330	6,120	8,560	8,368
Depreciation and amortization	2,400	600	—	—	—	—
Net cash from operating activities	(26,803)	(19,666)	(34,125)	(40,618)	(44,855)	(49,143)
Purchases of property and equipment	106	1,568	212	30	44	25
Net cash from investing activities	38	(1,770)	(151,200)	26,965	46,772	(93,306)
Proceeds from issuing common stock	60,482	128,267	76,237	3,126	18,113	137,999
Net cash from financing activities	48,538	118,611	75,757	2,935	17,338	129,609
Net change in cash	21,773	97,175	(109,568)	(10,718)	19,255	(12,840)

† Share count changed about 2x in the period ending 2021-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Compass Therapeutics	35,453	not reported	(14,738)*	180.1M	12.2 quarters	Q2 FY26 10-QJun 30, 2026
Ocugen	24,632	1,951	(15,739)*	339.3M	5.1 quarters	Q3 FY26 10-QSep 30, 2026
Abeona Therapeutics	56,229	11,380	(17,496)*	57.2M	8.4 quarters	Q2 FY26 10-QJun 30, 2026
Tonix Pharmaceuticals Holding	176,232	13,544	(42,243)*	17.2M	4.2 quarters	Q2 FY26 10-QJun 30, 2026
Vanda Pharmaceuticals	61,933	69,815	(28,435)*	60.5M	1.7 quarters	Q3 FY26 10-QSep 30, 2026
Standard Biotools	267,487	19,385	(6,161)*	394.8M	21.6 quarters	Q3 FY26 10-QSep 30, 2026
Aquestive Therapeutics	90,349	7,557	(7,046)*	125.7M	8.4 quarters	Q3 FY26 10-QSep 30, 2026
Atea Pharmaceuticals	76,548	not reported	(37,084)*	80.2M	5.9 quarters	Q2 FY26 10-QJun 30, 2026
Siga Technologies	117,584	41,002	15,174*	71.8M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.